Duminuco, A.; Scarso, S.; Cupri, A.; Parrinello, N.L.; Villari, L.; Scuderi, G.; Giunta, G.; Leotta, S.; Milone, G.A.; Giuffrida, G.;
et al. Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients. J. Clin. Med. 2023, 12, 578.
https://doi.org/10.3390/jcm12020578
AMA Style
Duminuco A, Scarso S, Cupri A, Parrinello NL, Villari L, Scuderi G, Giunta G, Leotta S, Milone GA, Giuffrida G,
et al. Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients. Journal of Clinical Medicine. 2023; 12(2):578.
https://doi.org/10.3390/jcm12020578
Chicago/Turabian Style
Duminuco, Andrea, Salvatore Scarso, Alessandra Cupri, Nunziatina Laura Parrinello, Loredana Villari, Grazia Scuderi, Giuliana Giunta, Salvatore Leotta, Giulio Antonio Milone, Giulia Giuffrida,
and et al. 2023. "Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients" Journal of Clinical Medicine 12, no. 2: 578.
https://doi.org/10.3390/jcm12020578
APA Style
Duminuco, A., Scarso, S., Cupri, A., Parrinello, N. L., Villari, L., Scuderi, G., Giunta, G., Leotta, S., Milone, G. A., Giuffrida, G., Palumbo, G. A., & Milone, G.
(2023). Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients. Journal of Clinical Medicine, 12(2), 578.
https://doi.org/10.3390/jcm12020578
